Molecular structure of Abemaciclib, CAS Number: 1231929-97-7
Abemaciclib (CAS 1231929-97-7)
Alternate Names:
LY2835219
CAS Number:
1231929-97-7
Molecular Weight:
506.59
Molecular Formula:
C27H32F2N8
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Abemaciclib (CAS 1231929-97-7) References
- MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. | Dickler, MN., et al. 2017. Clin Cancer Res. 23: 5218-5224. PMID: 28533223
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Sledge, GW., et al. 2017. J Clin Oncol. 35: 2875-2884. PMID: 28580882
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). | Johnston, SRD., et al. 2020. J Clin Oncol. 38: 3987-3998. PMID: 32954927
- Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. | Rugo, HS., et al. 2021. Oncologist. 26: e53-e65. PMID: 32955138
- Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. | Groenland, SL., et al. 2020. Clin Pharmacokinet. 59: 1501-1520. PMID: 33029704
- MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. | Zhang, QY., et al. 2020. Ther Adv Med Oncol. 12: 1758835920963925. PMID: 33149768
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. | Braal, CL., et al. 2021. Drugs. 81: 317-331. PMID: 33369721
- Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. | Wander, SA., et al. 2021. J Natl Compr Canc Netw. 1-8. PMID: 33761455
- Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. | Tolaney, SM., et al. 2022. Clin Cancer Res. 28: 1500-1506. PMID: 35121623
- Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. | Martin, M., et al. 2022. JAMA Oncol. 8: 1190-1194. PMID: 35653145
Inhibitor of:
4932411N23Rik, 4933404M19Rik, 4933411G11Rik, ABC1, C12orf63, C20orf43, C430048L16Rik, CCDC167, CCNJL, CCRK, Cdc123, Cdc28, Cdk4, Cdk6, CdkL4, Cdx2, Cdx4, CIRP, Cks2, CMBL, CNTD1, cyclin δ-1, cyclin δ-2, cyclin δ-3, cyclin A-type, Cyclin A1, cyclin D, cyclin D1, cyclin D2, cyclin D3, cyclin E, cyclin E2, cyclin F, cyclin G1, cyclin M4, cyclin Y, cyclin YL3, D1Ertd622e, DABP, DAN, Dcpp2, DKFZp761E198, DMXL1, DNB5, E2F-1, E2F-8, EG435366, FAM117A, FAM127B, FAM149B1, GEMC1, Gm606, GMD, GPN3, HST, Kazrin, Ki-67, LAGE-3, LDOC1, LIN-52, LIN37, LOC341346, LOC441150, MCEMP1, MIPU1, MPc3_CBX8, Olr1204, Olr170, Olr1739, Olr694, Olr744, Olr951, p130, p15, p21, p27, p57, PCTAIRE-2, Pinch-2, POGZ, Proliferation Marker, RBBP9, Repetin, RIA1, RPRC1, SERTAD4, Set1, Six5, Sp3, SPC12, SS18L2, TCHHL1, TOB1, WDR66, ZNF2, ZNF20, ZNF264, ZNF486, and ZNF492.Activator of:
Cdk10, Cig2, Cks1, cyclin δ-1, cyclin E, cyclin YL3, LIN-54, and Speedy A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Abemaciclib, 10 mg | sc-507342 | 10 mg | $110.00 |